Αρχική World News Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed... World News Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL Από Ogkologos - 6 Δεκεμβρίου, 2024 942 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the STARGLO study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR High HPV Vaccination Coverage in England Associated with a Substantial Reduction... 25 Ιουνίου, 2026 A tribute to Professor Anne Charlton 23 Ιουνίου, 2020 FDA Approves Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma 19 Νοεμβρίου, 2021 Running a cancer helpline in COVID-19: two years on the virtual... 23 Μαρτίου, 2022 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Talquetamab Lion With Skin Cancer Has Received Radiation Therapy In Hospital FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer Can Using Essential Oils Help Treat Cancer and Its Side Effects?